Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Effect of statin therapy with simvastatin or atorvastatin on analytes in non-PSEN1 and PSEN1 subjects

From: Prevention of Alzheimer's disease in high risk groups: statin therapy in subjects with PSEN1 mutations or heterozygosity for apolipoprotein E epsilon 4

 

Primary objective

Drug effect

Controlled for lipids

 

Statins

Atorvastatin

Simvastatin

Atorvastatin

Simvastatin

Analyte

% change

P -value

% change

P -value

% change

P -value

% change

P -value

% change

P -value

Non-PSEN1

          

   sAPPα

7

0.013

-

NS

13.1

0.019

9.6

0.0082

23.7

0.0005

   sAPPβ

-

NS

-

NS

-

NS

-

NS

-

NS

   Phospho-tau

-

NS

-

NS

-

NS

-

NS

-

NS

   Total tau

-

NS

-

NS

-

NS

-

NS

-

NS

   AB42

-

NS

-

NS

-

NS

-

NS

-

NS

PSEN1

          

   sAPPα

-16.5

0.0014

-

NS

-26.5

0.0002

-

NS

-24.1

0.0003

   sAPPβ

-21.2

0.0005

-

NS

-31.5

0.0001

-

NS

-

NS

   Phospho-tau

-8.3

0.076

-

NS

-

NS

-

NS

-

NS

   Total tau

-

NS

-

NS

-

NS

-

NS

-

NS

   AB42

-

NS

-

NS

-

NS

-

NS

-

NS

  1. Aβ42 = amyloid-beta 42; NS, not significant; sAPP, soluble amyloid precursor protein.
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193